Figure 3From: The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials Forest plot for the aggregate response data of crizotinib in the treatment of patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (A) overall response rate (ORR); (B) partial response; (C) complete response; (D) stable disease.Back to article page